Royalty Pharma officer proposes $508K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc officer Marshall Urist reported a proposed sale of 9,099 common shares, with an aggregate market value of $508,453.82 and an approximate sale date of July 1, 2026. Merrill Lynch is named as broker. The Rule 10b5-1 plan adoption or instruction date is February 12, 2026.
Separately, Marshall Urist acquired 9,099 Class A Ordinary Shares on May 8, 2026, through an Equity Performance Award granted as part of Royalty Pharma plc’s equity compensation program.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Equity Performance Award technical
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior RPRX sales did Marshall Urist report?
AI-generated analysis. How Rhea-AI works. Not financial advice.